CAR-T Cell Therapy

Category: technique

Chimeric Antigen Receptor T-cell therapy — engineering a patient's own T cells to recognize and attack cancer cells through synthetic antigen receptors.

Mechanism Detail

T cells are extracted, genetically modified to express a chimeric antigen receptor (CAR) targeting a tumor-associated antigen, expanded ex vivo, and reinfused. Next-gen designs include armored CARs (secreting cytokines), logic-gated CARs (AND/OR gates for specificity), and allogeneic off-the-shelf approaches.

Clinical Status

FDA-approved for B-cell lymphomas, ALL, and multiple myeloma. Solid tumor CAR-T remains challenging. Clinical trials for mesothelin, HER2, GD2, and claudin 18.2 targets.

Relevant Diseases

• Stage IV Cancer

Relevant Therapies

• Gene Therapy
• Cell-Based Therapies

Related Terms

• Chimeric antigen receptor
• T cell engineering
• Tumor microenvironment
• Cytokine release syndrome